SciClone and Taiwan Liposome link up on ProFlow for China

USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) yesterday (June 25) announced an agreement with biopharmaceutical company Taiwan Liposome (TLC), which grants the US firm a license and the exclusive rights to promote, market, distribute and sell ProFlow, intended for the treatment of peripheral arterial disease (PAD), in China, Hong Kong and Macau.

Financial terms of the deal include clinical, regulatory and sales milestone payments up to an aggregate of $39.5 million. The accord will see TLC responsible for the manufacturing and supply, including potential clinical trials and regulatory activities, of ProFlow, a novel lipid emulsion-based formulation of prostaglandin E1 (PGE1), a vasodilator and platelet inhibitor. SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities.

SciClone’s chief executive Friedhelm Blobel said: “We are excited to add ProFlow to our product portfolio, as the cardiovascular market represents a large and growing commercial He added: “We believe that ProFlow has significant therapeutic and commercial advantages that differentiate it from other branded and generic competitors in the expanding PAD segment. We look forward to working with our partner TLC to bring this important medical advance to patients in need.”